共 50 条
Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma -: Results of a multicenter randomized prospective trial
被引:266
|作者:
Rhodes, LE
de Rie, M
Enström, Y
Groves, R
Morken, T
Goulden, V
Wong, GAE
Grob, JJ
Varma, S
Wolf, P
机构:
[1] Univ Manchester, Hope Hosp, Dermatol Ctr, Photobiol Unit, Salford M6 8HD, Lancs, England
[2] Royal Liverpool Univ Hosp, Dept Dermatol, Liverpool, Merseyside, England
[3] Univ Amsterdam, Acad Med Ctr, Dept Dermatol, NL-1105 AZ Amsterdam, Netherlands
[4] Norra Alvsborgs Lanssjukhus, Dept Dermatol, Trollhattan, Sweden
[5] UCL, Ctr Dermatol, London, England
[6] Haukeland Hosp, Dept Dermatol, N-5021 Bergen, Norway
[7] Leeds Gen Infirm, Dept Dermatol, Leeds, W Yorkshire, England
[8] Hop St Marguerite, Dept Dermatol, Marseille, France
[9] Univ Wales Hosp, Dept Dermatol, Cardiff CF4 4XW, S Glam, Wales
[10] Graz Univ, Dept Dermatol, Graz, Austria
关键词:
D O I:
10.1001/archderm.140.1.17
中图分类号:
R75 [皮肤病学与性病学];
学科分类号:
100206 ;
摘要:
Background: Photodynamic therapy (PDT) is increasingly used as a noninvasive treatment for nodular basal cell carcinoma (BCC), without a sound evidence base. Objective: To compare topical PDT, with the use of the sensitizer methyl aminolevulinate, and standard excision surgery in nodular BCC. Design: Prospective, randomized study. Setting: University dermatology departments. Patients: A total of 101 adults with previously untreated nodular BCC. Interventions: Patients received methyl aminolevulinate PDT (n = 52) or surgery (n = 49). The PDT was given twice, 7 days apart, with methyl aminolevulinate cream (160 mg/g) and 75 J/cm(2) red light (570-670 nm). Thirteen patients with a noncomplete response to PDT at 3 months (24% lesions) were retreated. Outcome Measures: Primary end point was clinically assessed lesion clearance at 3 months after treatment. Secondary end points were sustained response rate at 12 months and cosmetic outcome at 3 and 12 months. Results: Data from 97 patients (105 lesions) were included in the 3-month per-protocol analysis. Complete response rates did not differ significantly between groups (51/52 [98%] lesions with surgery vs 48/53 [91%] lesions with methyl aminolevulinate PDT; difference [95% confidence interval], 4.8% (-3.4% to 13.0%1; P = .25). At 12 months, tumor-free rates were 50 (96%) of 52 lesions with surgery vs 44 (83%) of 53 with methyl aminolevulinate PDT (P = .15). More patients treated with methyl aminolevulinate PDT than surgery had an excellent or good cosmetic outcome at all time points (significant at 12 and 24 months on patient assessment, P < .05, and at 3, 12, and 24 months on investigator evaluation, P < .001). At 24 months, 5 lesions that had initially cleared with methyl aminolevulinate PDT had recurred, compared with I after surgery. Conclusions: Methyl aminolevulinate PDT is an effective treatment for nodular BCC, and while there is a trend for higher recurrence with this modality, it conveys the advantage over surgery of better cosmesis.
引用
收藏
页码:17 / 23
页数:7
相关论文